We evaluated the antidiabetic effects of a mixed vegetable powder-formula I (MVP-FI), which is a dry powder mixture of over 65 kinds of vegetables and fruits, using the db/db type 2 diabetes mouse model. The db/db mice at 8-10 weeks of age were randomly divided into three groups: vehicle treatment, 1.575 g/kg MVP-FI treatment, and 3.15 g/kg MVP-FI treatment. During 12 days of treatment, we measured food intake and body weight changes, fasting blood glucose levels, and plasma lipid levels. Our results showed that the food intake and the body weight of MVP-FI-treated group were decreased gradually. Moreover, the fasting blood glucose level of the treated group was signifi cantly dropped to a normal level comparable to that of the lean mice. Furthermore, we also found that the plasma triglyceride level in the treated group was dropped, whereas the high-density lipoprotein (HDL) level was increased and total cholesterol/HDL-cholesterol ratio was decreased. Taken together, these results suggest that the diabetic conditions of the db/db mice have been improved after 12 days treatment with MVP-FI. The antihyperglycemic and antiobese activities of the MVP-FI, as demonstrated in the present study, may have important clinical implications for improving the management of type 2 diabetic patients.
Introduction
Diabetes, which causes substantial morbidity, mortality, and long-term complications, is a predominant public health concern. The disease is characterized by symptomatic glucose intolerance as well as alterations in lipid and protein metabolism. It is also an important risk factor for cardiovascular disease. With increasing rates of childhood and adult obesity, diabetes is likely to become even more prevalent over the coming decade Yeh et al 2003) .
Many herbal derivatives or mixtures have been documented in traditional Chinese medicine (TCM) as having clinical effectiveness in treating sugar imbalances in diabetes (Kimura et al 1999) . Some derivatives or mixtures have been found effective in treating water retention problems that often accompany diabetes . Some Chinese medicines such as Jiang-Tang-Ke-Li and Jin-Qi can reduce the insulin resistance and improve the apparent insulin activity Wang et al 2003) . To date, hundreds of plants and formulae have been reported that are being used in traditional Chinese medicine for the treatment of diabetes .
Mixed vegetable powder-formula I (MVP-FI) contains dry powder of over 65 kinds of vegetables and fruits including bean sprout, pumpkin, carrot, apple, guava, and papaya as reported in a recent study (Wang et al 2007) . The antioxidant properties of MVP-FI have also been evaluated based on the criteria of oxidative damages to plasmid DNA, protein oxidation, cell viability, and red blood cell deformability. The results indicated that MVP-FI extracts provide signifi cant protections against DNA oxidative damages and the decreases of the erythrocyte deformability in a concentration-dependent manner (Wang et al 2007) . The aim of our present study was to evaluate the potential antidiabetic effects of MVP-FI in the db/db mice, a genetically obese diabetic mouse model. Our results clearly demonstrated that the diabetic conditions of the db/db mice were signifi cantly improved after 12 days of treatment with MVP-FI.
Materials and methods

Housing and care of animals
Male C57BLKS/J db/db mice were obtained from Jackson Laboratory (Bar Harbor, ME, USA). Wild-type C57BL/6J mice were purchased from the Laboratory Animal Unit of the University of Hong Kong. Mice were housed (3-5 mice per cage) in environmentally controlled conditions with a 12-h light/dark cycle and had free access to standard rodent pellet food and water, except when fasted before experiments. Adult animals at 8-10 weeks of age were used. All animal experiments were approved by the University of Hong Kong animal ethics committee on animal research.
Drug preparation and treatment
Mixed vegetable powder-formula I (MVP-FI) was kindly provided by Tangeles Biochemical Ltd. Co. (Taiwan, Republic of China). Before each experiment, MVP-FI was freshly dissolved in distilled water (189 g/ml) and used immediately to treat the mice. Male C57BLKS/J db/db mice and wild type C57BL/6J lean mice were divided randomly and were treated orally by gavage with either 3.15 g MVP-FI per kg of mouse (High-dose group, n = 4), or 1.575 g MVP-FI per kg of mouse (Low-dose group, n = 3), or vehicle only (Control group, n = 4), once daily for 12 days. For the treatment in C57BL/6J mice, they were gavaged with 3.15 g MVP-FI per kg of mouse.
Measurement of food intake and body weight changes, fasting blood glucose levels, and plasma lipid levels
The food intake and the body weight of each mouse were measured every one or two days. Fasting blood glucose levels were measured in tail blood samples of the mice fasted for 4 h on day 6 (during treatment) and day 12 (last day of treatment). Blood glucose levels were determined using the ONETOUCH Ultra Blood Glucose Monitoring System (LifeScan Inc., Milpitas, CA, USA). For the measurement of plasma lipid levels on day 0 (before treatment) and day 12 (last day of treatment), blood samples were collected from the retro-orbital sinus of the mice. Isofl urane was used to anesthetize animals prior to blood collection. Plasma was separated by centrifugation. Total cholesterol (TC), triglyceride, high-density lipoprotein-cholesterol (HDL-C), and low-density lipoprotein-cholesterol (LDL-C) levels were measured using standard assays.
Intraperitoneal glucose tolerance test
Intraperitoneal glucose tolerance test (IPGTT) was performed on day 12. Animals were fasted overnight and then received intraperitoneal administration of glucose (2 g/kg). Blood glucose levels were determined using the ONETOUCH Ultra Blood Glucose Monitoring System (LifeScan Inc.) from the tail blood samples at 0 (before glucose administration), 30, 60, 90, and 120 min after the glucose administration.
Statistical analysis
Data are expressed as mean ± standard error and analyzed by Student's t test and ANOVA, with P < 0.05 considered statistically signifi cant.
Results
Effect of MVP-FI on food intake and body weight
After MVP-FI treatment, the food intake of the mice was decreased signifi cantly ( Figure 1 ). The average body weight of adult db/db mice is almost twice of that of the wild-type C57BL/6J lean mice. The effects of MVP-FI on body weight changes in the db/db mice were shown in Figure 2 . On day 0, there was no signifi cant difference among all Figure 1 Effect of MVP-FI on the food intake of db/db mice and wild-type C57 lean mice. The food intake of the vehicle-treated group and lean group showed a slight tendency to decrease from day 0 to day 12. But the food intake of both 1.575 g/kg and 3.15 g/kg MVP-FI-treated groups decreased obviously. (Vehicle: n = 4, MVP-FI 1.575 g/kg: n = 3, MVP-FI 3.15 g/kg: n = 4, C57BL/6J lean mice: n = 5). Abbreviation: MVP-FI, mixed vegetable powder-formula I. Food intake (g)
the treatment groups. The body weights of animals in both the vehicle-treated control group and the lean mice group showed a slight tendency to increase from day 0 to day 12. Contrastingly, the body weights in both the high-dose and low-dose MVP-FI treatment groups were gradually reduced. From day 6, the body weights of 3.15 g/kg MVP-FI-treated db/db mice decreased signifi cantly. On day 10 and day 11, the body weights of both treatment groups decreased signifi cantly.
Effect of MVP-FI on fasting blood glucose level
Fasting blood glucose levels in the db/db mice and wildtype C57BL/6J lean mice were measured on day 6 and day 12 after the daily treatment with MVP-FI or vehicle. As shown in Figure 3 , db/db mice treated with vehicle had signifi cantly higher fasting blood glucose levels than that of the lean mice. On both day 6 and day 12, blood glucose concentrations decreased signifi cantly in db/db mice treated with 3.15 g/kg or 1.575 g/kg MVP-FI when comparing with the vehicle treatment group. The db/db mice, treated with either 3.15 g/kg or 1.575 g/kg MVP-FI, were normoglycemic. There was also no signifi cant difference in the fasting blood glucose levels between the MVP-FI-treated db/db mice and the wild-type C57BL/6J lean mice. Furthermore, the blood glucose concentrations of the wild-type C57BL/6J lean mice were not affected in response to the treatment with MVP-FI.
Effect of MVP-FI on plasma HDL-C, triglyceride levels, and TC/HDL-C ratio
After 12-day treatment, the plasma HDL-C concentrations in 3.15 g/kg MVP-FI-treated db/db mice were increased (Figure 4) . Moreover, the HDL-C levels were signifi cantly higher than those in the vehicle-treated animals. MVP-FI also signifi cantly reduced the plasma triglyceride levels in the db/db mice ( Figure 5 ). There were no signifi cant changes in the plasma TC level after treatment with either 1.575 g/kg or 3.15 g/kg MVP-FI (data not shown). But after 12 days of treatment, TC/HDL-C ratios of vehicle-treated group increased signifi cantly, and TC/HDL-C ratios of 3.15 g/kg MVP-FI-treated group decreased signifi cantly. There were no signifi cant changes in 1.575 g/kg MVP-FI-treated group (Figure 6 ). On day 12, TC/HDL-C ratios of both 1.575 g/kg and 3.15 g/kg MVP-FI-treated groups also decreased signifi cantly when comparing with that of vehicle-treated group.
Effect of 12-day treatment of MVP-FI on the glucose tolerance test
Glucose tolerance was evaluated by IPGTT after the 12-day treatment in the db/db mice. There was no improvement observed in the mice treated with either low or 3.15 g/kg MVP-FI (Figure 7 ).
Discussion
The present study was undertaken to investigate the antidiabetic effects of the TCM formula, MVP-FI, using the type 2 diabetic db/db mouse model. Our present data clearly demonstrate that MVP-FI signifi cantly improves glucose Figure 2 Effect of MVP-FI on the body weight of db/db mice and wild-type C57BL/6J lean mice. The body weights of the vehicle-treated group and lean group showed a slight tendency to increase from day 0 to day 12. However, the body weights of the MVP-FItreated groups were decreased gradually during the treatment period. Figure 3 Effect of MVP-FI on the fasting blood glucose concentrations in adult db/db mice and wild-type C57BL/6J lean mice. On day 6, glucose levels decreased signifi cantly both in 3.15 g/kg (n = 4, 8.7 ± 1.7 mmol/L) and 1.575 g/kg (n = 3, 8.05 ± 0.65 mmol/L) MVP-FI-treated db/db mice (P Ͻ 0.05 vs. vehicle-treated mice, n = 4, 21 ± 3.48 mmol/L), and there was no signifi cant difference in the levels between MVP-FI-treated db/db mice and wild-type C57BL/6J lean mice (n = 5, 6.97 ± 0.2 mmol/L, P > 0.05). On day 12, fasting blood glucose levels of 3.15 g/kg MVP-FI-treated db/db mice (5.8 ± 1.7 mmol/L) and 1.575 g/kg MVP-FI-treated db/db mice (9.45 ± 1.5 mmol/L) also had signifi cant decreases when comparing with those of the control db/db mice (treated with vehicle, 18 ± 4.7 mmol/L, P Ͻ 0.05) and had no signifi cant difference comparing with lean mice (8.87 ± 1.1 mmol/L, P Ͼ 0.05). Abbreviation: MVP-FI, mixed vegetable powder-formula I. The results also showed that lean littermate control mice were not sensitive to the glucose-lowering effects caused by MVP-FI. Furthermore, MVP-FI has noticeably good effects on the plasma HDL-C levels and the triglyceride levels. After the treatment period, the plasma HDL-C concentrations were increased (Figure 3 ), whereas the plasma triglyceride levels were decreased (Figure 4) . It is estimated that more than 200 species of plants exhibit hypoglycemic properties, including many common plants, such as pumpkin, wheat, celery, wax guard, lotus root, bitter melon, ginseng, and papaya (Savickiene et al 2002; Jia et al 2003) . MVP-FI is a traditional Chinese medicine formula that contains a mixture of over 65 kinds of vegetables and fruits including pumpkin, carrot, apple, guava, and papaya, which has been suggested as a drug with nourishing effects, especially on the growth and development of the body. It has also been found that high fi bre fruit guava has hypoglycemic effect in both mice and human subjects (Cheng and Yang 1983; Yusof and Said 2004) . In general, traditional Chinese medicines are complex mixtures of different compounds that often act in a synergistic fashion (Tsuneki et al 2004) .
In our present study, we found that the body weights of MVP-FI-treated groups were decreased (Figure 2 ). Effect of MVP-FI on the TC/HDL-C ratios in the db/db mice. Before treatment, there was no signifi cant difference in the TC/HDL-C ratios between MVP-FI treatment groups and vehicle-treated group (MVP-FI 1.575 g/kg: 7.2 ± 0.8, vehicle: 6.9 ± 1.0, P Ͼ 0.05; MVP-FI 3.15 g/kg: 6.8 ± 0.8, vehicle: 6.9 ± 1.0 g, P Ͼ 0.05). After 12 days of treatment, TC/HDL-C ratios of vehicle-treated group increased signifi cantly (Day 12: 9.32 ± 1.0, Day 0: 6.9 ± 1.0 g, a, P Ͻ 0.05), and TC/HDL-C ratios of 3.15 g/kg MVP-FItreated group decreased signifi cantly (Day 12: 4.6 ± 0.08, Day 0: 6.8 ±0.8, b, P Ͻ 0.05). There were no signifi cant changes in 1.575 g/kg MVP-FI-treated group (Day 12: 6.1 ± 0.5, Day 0: 7.2 ± 0.8, P Ͼ 0.05). On day 12, TC/HDL-C ratios of both 1.575 g/kg (6.1 ± 0.5 vs. vehicle-treated group 9.32 ± 1.0, c, P Ͻ 0.01) and 3.15 g/kg (4.6 ± 0.08 vs. vehicle-treated group 9.32 ± 1.0, d, P Ͻ 0.01) MVP-FI-treated groups also decreased signifi cantly when comparing with that of vehicle-treated group. (Vehicle: n = 4, MVP-FI 1.575 g/kg: n = 3, MVP-FI 3.15 g/kg: n = 4). Abbreviations: HDL-C, high-density lipoprotein-cholesterol; MVP-FI, mixed vegetable powder-formula I; TC, total cholesterol. 
